Xvivo Perfusion AB (XVIVO) - Total Liabilities
Based on the latest financial reports, Xvivo Perfusion AB (XVIVO) has total liabilities worth Skr260.65 Million SEK (≈ $28.05 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Xvivo Perfusion AB (XVIVO) cash conversion ratio to assess how effectively this company generates cash.
Xvivo Perfusion AB - Total Liabilities Trend (2011–2025)
This chart illustrates how Xvivo Perfusion AB's total liabilities have evolved over time, based on quarterly financial data. Check XVIVO financial resilience to evaluate the company's liquid asset resilience ratio.
Xvivo Perfusion AB Competitors by Total Liabilities
The table below lists competitors of Xvivo Perfusion AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alarko Holding AS
IS:ALARK
|
Turkey | TL43.30 Billion |
|
Dynavox Group
ST:DYVOX
|
Sweden | Skr1.39 Billion |
|
Morguard Corporation
TO:MRC
|
Canada | CA$7.07 Billion |
|
Zhejiang Xinao Textiles Inc
SHG:603889
|
China | CN¥2.63 Billion |
|
Sensirion Holding AG
SW:SENS
|
Switzerland | CHF67.30 Million |
|
Voltalia SA
PA:VLTSA
|
France | €2.86 Billion |
|
Surya Citra Media Tbk
JK:SCMA
|
Indonesia | Rp1.95 Trillion |
|
Genco Shipping & Trading Ltd
NYSE:GNK
|
USA | $220.30 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Xvivo Perfusion AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Xvivo Perfusion AB worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 2.45 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Xvivo Perfusion AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Xvivo Perfusion AB (2011–2025)
The table below shows the annual total liabilities of Xvivo Perfusion AB from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr260.65 Million ≈ $28.05 Million |
+5.97% |
| 2024-12-31 | Skr245.97 Million ≈ $26.47 Million |
-1.84% |
| 2023-12-31 | Skr250.57 Million ≈ $26.96 Million |
-17.29% |
| 2022-12-31 | Skr302.95 Million ≈ $32.60 Million |
+17.81% |
| 2021-12-31 | Skr257.15 Million ≈ $27.67 Million |
+81.28% |
| 2020-12-31 | Skr141.85 Million ≈ $15.27 Million |
+149.00% |
| 2019-12-31 | Skr56.97 Million ≈ $6.13 Million |
+23.48% |
| 2018-12-31 | Skr46.13 Million ≈ $4.96 Million |
+34.87% |
| 2017-12-31 | Skr34.21 Million ≈ $3.68 Million |
+4.03% |
| 2016-12-31 | Skr32.88 Million ≈ $3.54 Million |
+70.33% |
| 2015-12-31 | Skr19.31 Million ≈ $2.08 Million |
-24.34% |
| 2014-12-31 | Skr25.52 Million ≈ $2.75 Million |
-17.50% |
| 2013-12-31 | Skr30.93 Million ≈ $3.33 Million |
+20.10% |
| 2012-12-31 | Skr25.75 Million ≈ $2.77 Million |
-80.03% |
| 2011-12-31 | Skr128.97 Million ≈ $13.88 Million |
-- |
About Xvivo Perfusion AB
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidn… Read more